Sign In
Buy VNDA
$6.00
-0.240 (-3.85%)
At Close: Jul 13, 2026
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
04:30pm, Friday, 10'th Jul 2026
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designati
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
07:00am, Wednesday, 27'th May 2026
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designatio
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
01:34pm, Wednesday, 13'th May 2026
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio off
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
06:44pm, Thursday, 07'th May 2026
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May 2026:
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
05:01am, Thursday, 07'th May 2026
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 06'th May 2026
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
04:01pm, Wednesday, 06'th May 2026
Fanapt ® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76% NEREUS™ (tradipitant) launched via nereus.us, an innovative direct-
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
10:55am, Tuesday, 05'th May 2026
The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now co
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now co
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
04:30pm, Wednesday, 29'th Apr 2026
Conference Call and Webcast to Follow WASHINGTON, April 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2026 on
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Apr 2026
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
05:13pm, Wednesday, 22'nd Apr 2026
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 202
